Currently out of the existing stock ratings of Paul Matteis, 339 are a BUY (73.38%), 123 are a HOLD (26.62%).

Paul Matteis

Work Performance Price Targets & Ratings Chart

Analyst Paul Matteis, currently employed at STIFEL, carries an average stock price target met ratio of 51.54% that have a potential upside of 44.37% achieved within 244 days.

Paul Matteis’s has documented 885 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Basic Materials, Consumer Defensive sectors.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 31-Jul-2026.

Wall Street Analyst Paul Matteis

Analyst best performing recommendations are on WVE (WAVE LIFE SCIENCES LTD).
The best stock recommendation documented was for WVE (WAVE LIFE SCIENCES LTD) at 4/16/2019. The price target of $26 was fulfilled within 1 day with a profit of $1.53 (6.25%) receiving and performance score of 62.53.

Average potential price target upside

of $172 (59.92%) on NLTX (NEOLEUKIN THERAPEUTICS).
of $37.17 (41.16%) on GWPH (GW PHARMACEUTICALS PLC).
of $37.05 (31.66%) on KRTX (KARUNA THERAPEUTICS).

ACAD ACADIA Pharmaceuticals ACOR Acorda Therapeutics ALKS Alkermes Plc ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals ATHA Athira Pharma BIIB Biogen BMRN Biomarin Pharmaceutical CERE Cerevel Therapeutics Holdings GWPH GW Pharmaceuticals plc IONS Ionis Pharmaceuticals KRTX Karuna Therapeutics NBIX Neurocrine Biosciences PRVL Prevail Therapeutics SAGE Sage Therapeutic VRTX Vertex Pharmaceuticals ZGNX Zogenix AVDL Avadel Pharmaceuticals PLC DYN Dyne Therapeutics KALV Kalvista Pharmaceuticals GMTX Gemini Therapeutics QURE Uniqure NV ALEC Alector PRTK Paratek Pharmaceuticals ABOS Acumen Pharmaceuticals ELYM Eliem Therapeutics WVE Wave Life Sciences Ltd XENE Xenon Pharmaceuticals AKCA Akcea Therapeutics AKAO Achaogen CDTX Cidara Therapeutics DNLI Denali Therapeutics NBRV Nabriva Therapeutics AG OREX Orexigen Therapeutics PEPG PepGen Ltd GHRS GH Research PLC ANRO Alto Neuroscience NGNE Neurogene ALDR Alder BioPharmaceuticals FATE Fate Therapeutics ITCI Intracellular Th NLTX Neoleukin Therapeutics RYTM Rhythm Pharmaceuticals VIGL Vigil Neuroscience AKA AKA Brands Holding Corp AVD American Vanguard CE Celanese CMPS Compass Pathways Plc CTNM Contineum Therapeutics, Common Stock EL Estee Lauder Companies LXEO Lexeo Therapeutics, Common Stock NMRA Neumora Therapeutics SA Seabridge Gold TBPH Theravance Biopharma ZGN Ermenegildo Zegna NV

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jeffrey Hung (MORGAN STANLEY)

Hold Since 07-Mar-2025

$28

$0.17 (0.61%)

19 days ago
(25-Aug-2026)

24/30 (80%)

$-2.57 (-8.41%)

206

Please subscribe to see extended stock data

Yigal Nochomovitz (CITI)

Buy Since 21-Oct-2025

$40

$12.17 (43.73%)

$39

19 days ago
(25-Aug-2026)

0/6 (0%)

$9.43 (30.85%)

Please subscribe to see extended stock data

David Hoang (DEUTSCHE BANK)

Buy Since 25-Sep-2025

$38

$10.17 (36.54%)

$29

19 days ago
(25-Aug-2026)

2/5 (40%)

$7.43 (24.30%)

574

Please subscribe to see extended stock data

Ashwani Verma (UBS)

Buy Since 17-Oct-2023

$49

$21.17 (76.07%)

$40

27 days ago
(17-Aug-2026)

2/10 (20%)

$19.99 (68.91%)

467

Please subscribe to see extended stock data

Ami Fadia (NEEDHAM)

Buy Since 28-Feb-2024

$41

$13.17 (47.32%)

$29

1 months 1 days ago
(12-Aug-2026)

9/12 (75%)

$11.55 (39.22%)

393

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Paul Matteis most bullish on?

Potential upside of $69.32 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Paul Matteis most reserved on?

Potential downside of -$2.83 has been obtained for ACAD (ACADIA PHARMACEUTICALS)

What Year was the first public recommendation made by Paul Matteis?

On 2013